{
  "ticker": "PFE",
  "entities": [
    {
      "text": "Pfizer Inc.",
      "label": "ORG",
      "start": 0,
      "end": 11,
      "sentence": "Pfizer Inc. (NYSE:PFE) shares are reacting to a mix of clinical pipeline news, dividend and earnings updates, analyst ratings and legal developments.",
      "context": "Pfizer Inc. (NYSE:PFE) shares are reacting to a mix of clinic",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "PFE",
      "label": "ORG",
      "start": 18,
      "end": 21,
      "sentence": "Pfizer Inc. (NYSE:PFE) shares are reacting to a mix of clinical pipeline news, dividend and earnings updates, analyst ratings and legal developments.",
      "context": "Pfizer Inc. (NYSE:PFE) shares are reacting to a mix of clinical pipelin",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Zacks",
      "label": "ORG",
      "start": 202,
      "end": 207,
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "context": "re’s what’s moving the stock:\nPositive Sentiment:\nZacks highlights PFE’s strong earnings surprise history",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "PFE",
      "label": "ORG",
      "start": 219,
      "end": 222,
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "context": "g the stock:\nPositive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects an",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 308,
      "end": 314,
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "context": "and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?\nPositive Sentiment:\nP",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "PFE",
      "label": "ORG",
      "start": 316,
      "end": 319,
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "context": "cts another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?\nPositive Sentiment:\nPfizer",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 363,
      "end": 369,
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "context": "r (PFE) Beat Estimates Again?\nPositive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Astellas",
      "label": "ORG",
      "start": 374,
      "end": 382,
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "context": "t Estimates Again?\nPositive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 543,
      "end": 549,
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "context": "ostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Astellas",
      "label": "ORG",
      "start": 551,
      "end": 559,
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "context": "ancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Stu",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Xtandi",
      "label": "PRODUCT",
      "start": 567,
      "end": 573,
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "context": "mproved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Se",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 723,
      "end": 729,
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "context": "be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Chan",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "PFE",
      "label": "ORG",
      "start": 864,
      "end": 867,
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "context": "Sentiment:\nAn S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increa",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "6.7%",
      "label": "PERCENT",
      "start": 870,
      "end": 874,
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "context": "ent:\nAn S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase like",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "year-end",
      "label": "DATE",
      "start": 930,
      "end": 938,
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "context": "ated yield, with another small increase likely by year-end.\n“Nobody Ever Went Broke Taking a Profit” – Grab",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "1.7%",
      "label": "PERCENT",
      "start": 1069,
      "end": 1073,
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "context": "ocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 1123,
      "end": 1129,
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "context": "on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – S",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 1142,
      "end": 1148,
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "context": "valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?\nNeut",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "1.7%",
      "label": "PERCENT",
      "start": 1171,
      "end": 1175,
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "context": "f Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?\nNeutral Sentiment:\nCantor Fitzg",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Cantor Fitzgerald",
      "label": "ORG",
      "start": 1213,
      "end": 1230,
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "context": "ding Up 1.7% – Should You Buy?\nNeutral Sentiment:\nCantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 b",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "FY2025",
      "label": "DATE",
      "start": 1241,
      "end": 1247,
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "context": "y?\nNeutral Sentiment:\nCantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutra",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "3.09",
      "label": "MONEY",
      "start": 1274,
      "end": 1278,
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "context": "gerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "24",
      "label": "MONEY",
      "start": 1311,
      "end": 1313,
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "context": "slightly to $3.09 but keeps a Neutral rating and $24 price target.\nPfizer FY2025 EPS Forecast Decrease",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 1328,
      "end": 1334,
      "sentence": "Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:",
      "context": "but keeps a Neutral rating and $24 price target.\nPfizer FY2025 EPS Forecast Decreased by Cantor Fitzgeral",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "FY2025",
      "label": "DATE",
      "start": 1335,
      "end": 1341,
      "sentence": "Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:",
      "context": "eps a Neutral rating and $24 price target.\nPfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutr",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Cantor Fitzgerald",
      "label": "ORG",
      "start": 1368,
      "end": 1385,
      "sentence": "Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:",
      "context": "e target.\nPfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:\nBernstein reaffirms a Hold rat",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Bernstein",
      "label": "ORG",
      "start": 1405,
      "end": 1414,
      "sentence": "Bernstein reaffirms a Hold rating on PFE, citing steady cash flows and a deep drug pipeline.",
      "context": "Decreased by Cantor Fitzgerald\nNeutral Sentiment:\nBernstein reaffirms a Hold rating on PFE, citing steady cas",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "PFE",
      "label": "ORG",
      "start": 1442,
      "end": 1445,
      "sentence": "Bernstein reaffirms a Hold rating on PFE, citing steady cash flows and a deep drug pipeline.",
      "context": "l Sentiment:\nBernstein reaffirms a Hold rating on PFE, citing steady cash flows and a deep drug pipelin",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Bernstein",
      "label": "ORG",
      "start": 1498,
      "end": 1507,
      "sentence": "Bernstein Sticks to Its Hold Rating for Pfizer (PFE)\nNegative Sentiment:",
      "context": "iting steady cash flows and a deep drug pipeline.\nBernstein Sticks to Its Hold Rating for Pfizer (PFE)\nNegati",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 1538,
      "end": 1544,
      "sentence": "Bernstein Sticks to Its Hold Rating for Pfizer (PFE)\nNegative Sentiment:",
      "context": "pipeline.\nBernstein Sticks to Its Hold Rating for Pfizer (PFE)\nNegative Sentiment:\nThe stock dipped 1.3% a",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "1.3%",
      "label": "PERCENT",
      "start": 1588,
      "end": 1592,
      "sentence": "The stock dipped 1.3% amid profit-taking and sell-side caution over valuation.",
      "context": "Pfizer (PFE)\nNegative Sentiment:\nThe stock dipped 1.3% amid profit-taking and sell-side caution over val",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 1650,
      "end": 1656,
      "sentence": "Pfizer (NYSE:PFE) Stock Price Down 1.3% – Here's Why\nNegative Sentiment:",
      "context": "ofit-taking and sell-side caution over valuation.\nPfizer (NYSE:PFE) Stock Price Down 1.3% – Here's Why\nNeg",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "1.3%",
      "label": "PERCENT",
      "start": 1685,
      "end": 1689,
      "sentence": "Pfizer (NYSE:PFE) Stock Price Down 1.3% – Here's Why\nNegative Sentiment:",
      "context": "ver valuation.\nPfizer (NYSE:PFE) Stock Price Down 1.3% – Here's Why\nNegative Sentiment:\nPfizer and BioNT",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 1723,
      "end": 1729,
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "context": "Price Down 1.3% – Here's Why\nNegative Sentiment:\nPfizer and BioNTech appeal a UK patent ruling favoring M",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "BioNTech",
      "label": "ORG",
      "start": 1734,
      "end": 1742,
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "context": "1.3% – Here's Why\nNegative Sentiment:\nPfizer and BioNTech appeal a UK patent ruling favoring Moderna, exten",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "UK",
      "label": "GPE",
      "start": 1752,
      "end": 1754,
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "context": "Negative Sentiment:\nPfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal u",
      "is_company": false,
      "is_person": false,
      "is_location": true,
      "is_financial": false
    },
    {
      "text": "Moderna",
      "label": "ORG",
      "start": 1778,
      "end": 1785,
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "context": "r and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vacc",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Pfizer",
      "label": "ORG",
      "start": 1850,
      "end": 1856,
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "context": "al uncertainty around COVID-19 vaccine royalties.\nPfizer, BioNTech ask UK court to overturn Moderna's COVI",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "BioNTech",
      "label": "ORG",
      "start": 1858,
      "end": 1866,
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "context": "tainty around COVID-19 vaccine royalties.\nPfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "UK",
      "label": "GPE",
      "start": 1871,
      "end": 1873,
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "context": "COVID-19 vaccine royalties.\nPfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent",
      "is_company": false,
      "is_person": false,
      "is_location": true,
      "is_financial": false
    },
    {
      "text": "Moderna",
      "label": "ORG",
      "start": 1892,
      "end": 1899,
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "context": "alties.\nPfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "1+ days ago",
      "label": "DATE",
      "start": 1934,
      "end": 1945,
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "context": "verturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated. May Contain Errors.",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    }
  ],
  "relationships": [
    {
      "type": "SVO",
      "subject": "what",
      "verb": "moving",
      "object": "stock",
      "sentence": "Here’s what’s moving the stock:",
      "importance": 1
    },
    {
      "type": "SVO",
      "subject": "Zacks",
      "verb": "highlights",
      "object": "history",
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "importance": 5
    },
    {
      "type": "SVO",
      "subject": "Pfizer",
      "verb": "Beat",
      "object": "Estimates",
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "importance": 5
    },
    {
      "type": "SVO",
      "subject": "Pfizer",
      "verb": "report",
      "object": "results",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "importance": 8
    },
    {
      "type": "SVO",
      "subject": "Pfizer",
      "verb": "Report",
      "object": "Win",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "importance": 8
    },
    {
      "type": "SVO",
      "subject": "roundup",
      "verb": "highlights",
      "object": "yield",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "importance": 10
    },
    {
      "type": "SVO",
      "subject": "You",
      "verb": "Buy",
      "object": "Pfizer",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "importance": 12
    },
    {
      "type": "SVO",
      "subject": "Fitzgerald",
      "verb": "trims",
      "object": "forecast",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "importance": 8
    },
    {
      "type": "SVO",
      "subject": "Bernstein",
      "verb": "reaffirms",
      "object": "rating",
      "sentence": "Bernstein reaffirms a Hold rating on PFE, citing steady cash flows and a deep drug pipeline.",
      "importance": 5
    },
    {
      "type": "SVO",
      "subject": "Pfizer",
      "verb": "appeal",
      "object": "ruling",
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "importance": 4
    },
    {
      "type": "SVO",
      "subject": "Pfizer",
      "verb": "ask",
      "object": "court",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "importance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Inc.",
      "entity2_type": "ORG",
      "sentence": "Pfizer Inc. (NYSE:PFE) shares are reacting to a mix of clinical pipeline news, dividend and earnings updates, analyst ratings and legal developments.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "PFE",
      "entity2_type": "ORG",
      "sentence": "Pfizer Inc. (NYSE:PFE) shares are reacting to a mix of clinical pipeline news, dividend and earnings updates, analyst ratings and legal developments.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Inc.",
      "entity1_type": "ORG",
      "entity2": "PFE",
      "entity2_type": "ORG",
      "sentence": "Pfizer Inc. (NYSE:PFE) shares are reacting to a mix of clinical pipeline news, dividend and earnings updates, analyst ratings and legal developments.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "PFE",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "PFE",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "PFE",
      "entity1_type": "ORG",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "PFE",
      "entity1_type": "ORG",
      "entity2": "PFE",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "PFE",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Astellas",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Astellas",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Xtandi",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 63
    },
    {
      "type": "co-occurrence",
      "entity1": "Astellas",
      "entity1_type": "ORG",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "Astellas",
      "entity1_type": "ORG",
      "entity2": "Astellas",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "Astellas",
      "entity1_type": "ORG",
      "entity2": "Xtandi",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "Astellas",
      "entity1_type": "ORG",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 61
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Astellas",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Xtandi",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "Astellas",
      "entity1_type": "ORG",
      "entity2": "Xtandi",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Astellas",
      "entity1_type": "ORG",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "Xtandi",
      "entity1_type": "PRODUCT",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "PFE",
      "entity1_type": "ORG",
      "entity2": "6.7",
      "entity2_type": "PERCENT",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "PFE",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "PFE",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "PFE",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "PFE",
      "entity1_type": "ORG",
      "entity2": "end",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "6.7",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "6.7",
      "entity1_type": "PERCENT",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "6.7",
      "entity1_type": "PERCENT",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "6.7",
      "entity1_type": "PERCENT",
      "entity2": "end",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "end",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "end",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "end",
      "entity2_type": "DATE",
      "sentence": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "1.7",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "1.7",
      "entity1_type": "PERCENT",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "1.7",
      "entity1_type": "PERCENT",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "1.7",
      "entity1_type": "PERCENT",
      "entity2": "1.7",
      "entity2_type": "PERCENT",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "1.7",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "1.7",
      "entity2_type": "PERCENT",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "1.7",
      "entity2_type": "PERCENT",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "1.7",
      "entity2_type": "PERCENT",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "1.7",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "3.09",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "24",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "3.09",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "24",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "3.09",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "24",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "3.09",
      "entity1_type": "MONEY",
      "entity2": "24",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Cantor",
      "entity2_type": "ORG",
      "sentence": "Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "Cantor",
      "entity2_type": "ORG",
      "sentence": "Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Bernstein",
      "entity1_type": "ORG",
      "entity2": "PFE",
      "entity2_type": "ORG",
      "sentence": "Bernstein reaffirms a Hold rating on PFE, citing steady cash flows and a deep drug pipeline.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Bernstein",
      "entity1_type": "ORG",
      "entity2": "Pfizer",
      "entity2_type": "ORG",
      "sentence": "Bernstein Sticks to Its Hold Rating for Pfizer (PFE)\nNegative Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "1.3",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "The stock dipped 1.3% amid profit-taking and sell-side caution over valuation.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "1.3",
      "entity2_type": "PERCENT",
      "sentence": "Pfizer (NYSE:PFE) Stock Price Down 1.3% – Here's Why\nNegative Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Pfizer (NYSE:PFE) Stock Price Down 1.3% – Here's Why\nNegative Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "1.3",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Pfizer (NYSE:PFE) Stock Price Down 1.3% – Here's Why\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "BioNTech",
      "entity2_type": "ORG",
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "UK",
      "entity2_type": "GPE",
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Moderna",
      "entity2_type": "ORG",
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "BioNTech",
      "entity1_type": "ORG",
      "entity2": "UK",
      "entity2_type": "GPE",
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "BioNTech",
      "entity1_type": "ORG",
      "entity2": "Moderna",
      "entity2_type": "ORG",
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "UK",
      "entity1_type": "GPE",
      "entity2": "Moderna",
      "entity2_type": "ORG",
      "sentence": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "BioNTech",
      "entity2_type": "ORG",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "UK",
      "entity2_type": "GPE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "Moderna",
      "entity2_type": "ORG",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "1",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "+",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "days",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "Pfizer",
      "entity1_type": "ORG",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "BioNTech",
      "entity1_type": "ORG",
      "entity2": "UK",
      "entity2_type": "GPE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "BioNTech",
      "entity1_type": "ORG",
      "entity2": "Moderna",
      "entity2_type": "ORG",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "BioNTech",
      "entity1_type": "ORG",
      "entity2": "1",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "BioNTech",
      "entity1_type": "ORG",
      "entity2": "+",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "BioNTech",
      "entity1_type": "ORG",
      "entity2": "days",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "BioNTech",
      "entity1_type": "ORG",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "UK",
      "entity1_type": "GPE",
      "entity2": "Moderna",
      "entity2_type": "ORG",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "UK",
      "entity1_type": "GPE",
      "entity2": "1",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "UK",
      "entity1_type": "GPE",
      "entity2": "+",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "UK",
      "entity1_type": "GPE",
      "entity2": "days",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "UK",
      "entity1_type": "GPE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "Moderna",
      "entity1_type": "ORG",
      "entity2": "1",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Moderna",
      "entity1_type": "ORG",
      "entity2": "+",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Moderna",
      "entity1_type": "ORG",
      "entity2": "days",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Moderna",
      "entity1_type": "ORG",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "+",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "days",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "+",
      "entity1_type": "DATE",
      "entity2": "days",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "+",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "days",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "distance": 1
    }
  ],
  "key_phrases": [
    {
      "text": "a mix",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "clinical pipeline news",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "dividend and earnings updates",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "analyst ratings",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "legal developments",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "the stock",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "PFE’s strong earnings surprise history",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "another beat",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its next report",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "positive Phase 3 EMBARK trial results",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "non-metastatic hormone-sensitive prostate cancer",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "improved overall survival",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Xtandi Survival Win",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Prostate Cancer Study",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "New study data",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a game-changer",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "atopic dermatitis patients",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Pfizer’s New Study",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "A Potential Game-Changer",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Atopic Dermatitis",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "An S&P 500 dividend roundup",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "PFE’s 6.7% indicated yield",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "another small increase",
      "type": "noun_chunk",
      "category": "trend"
    },
    {
      "text": "a Profit",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "The Highest-Yielding S&P 500 Stocks",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "the strength",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Pfizer’s pipeline",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Cantor Fitzgerald",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its FY2025 EPS forecast",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a Neutral rating",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "$24 price target",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Pfizer FY2025 EPS Forecast",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Cantor Fitzgerald",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a Hold rating",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "steady cash flows",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a deep drug pipeline",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Its Hold Rating",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Negative Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "The stock",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "sell-side caution",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Negative Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a UK patent ruling",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "legal uncertainty",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "COVID-19 vaccine royalties",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "UK court",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Moderna's COVID vaccine patent",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "$3.09",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$24",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "6.7%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "1.7%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "1.7%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "1.3%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "1.3%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "FY2025",
      "type": "pattern",
      "category": "fiscal_year"
    },
    {
      "text": "FY2025",
      "type": "pattern",
      "category": "fiscal_year"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "Profit",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "profit",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "Trading",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "Stock",
      "type": "pattern",
      "category": "market_term"
    }
  ],
  "important_sentences": [
    {
      "text": "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:",
      "importance_score": 38,
      "entity_count": 6,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 5,
      "sentiment": "positive"
    },
    {
      "text": "“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now\nPositive Sentiment:\nShares climbed 1.7% on optimism around valuation and the strength of Pfizer’s pipeline.\nPfizer (NYSE:PFE) Trading Up 1.7% – Should You Buy?",
      "importance_score": 38,
      "entity_count": 6,
      "financial_keyword_count": 6,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "positive"
    },
    {
      "text": "Cantor Fitzgerald trims its FY2025 EPS forecast slightly to $3.09 but keeps a Neutral rating and $24 price target.",
      "importance_score": 33,
      "entity_count": 5,
      "financial_keyword_count": 3,
      "money_count": 2,
      "company_count": 1,
      "sentiment": "neutral"
    },
    {
      "text": "Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win\nPosted 1+ days ago\nAI Generated.",
      "importance_score": 31,
      "entity_count": 8,
      "financial_keyword_count": 1,
      "money_count": 0,
      "company_count": 3,
      "sentiment": "neutral"
    },
    {
      "text": "An S&P 500 dividend roundup highlights PFE’s 6.7% indicated yield, with another small increase likely by year-end.",
      "importance_score": 28,
      "entity_count": 6,
      "financial_keyword_count": 4,
      "money_count": 0,
      "company_count": 1,
      "sentiment": "positive"
    },
    {
      "text": "Positive Sentiment:\nZacks highlights PFE’s strong earnings surprise history and expects another beat in its next report.\nWill Pfizer (PFE) Beat Estimates Again?",
      "importance_score": 27,
      "entity_count": 4,
      "financial_keyword_count": 1,
      "money_count": 0,
      "company_count": 4,
      "sentiment": "positive"
    },
    {
      "text": "Pfizer Inc. (NYSE:PFE) shares are reacting to a mix of clinical pipeline news, dividend and earnings updates, analyst ratings and legal developments.",
      "importance_score": 26,
      "entity_count": 3,
      "financial_keyword_count": 4,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "Bernstein reaffirms a Hold rating on PFE, citing steady cash flows and a deep drug pipeline.",
      "importance_score": 21,
      "entity_count": 2,
      "financial_keyword_count": 3,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties.",
      "importance_score": 20,
      "entity_count": 4,
      "financial_keyword_count": 0,
      "money_count": 0,
      "company_count": 3,
      "sentiment": "neutral"
    },
    {
      "text": "Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald\nNeutral Sentiment:",
      "importance_score": 19,
      "entity_count": 4,
      "financial_keyword_count": 1,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    }
  ],
  "entity_statistics": {
    "total_entities": 42,
    "unique_entities": 19,
    "type_counts": {
      "ORG": 28,
      "PRODUCT": 1,
      "PERCENT": 5,
      "DATE": 4,
      "MONEY": 2,
      "GPE": 2
    },
    "type_distribution": {
      "ORG": 0.6666666666666666,
      "PRODUCT": 0.023809523809523808,
      "PERCENT": 0.11904761904761904,
      "DATE": 0.09523809523809523,
      "MONEY": 0.047619047619047616,
      "GPE": 0.047619047619047616
    },
    "most_common_entities": [
      [
        "Pfizer",
        11
      ],
      [
        "PFE",
        5
      ],
      [
        "Astellas",
        2
      ],
      [
        "1.7%",
        2
      ],
      [
        "Cantor Fitzgerald",
        2
      ],
      [
        "FY2025",
        2
      ],
      [
        "Bernstein",
        2
      ],
      [
        "1.3%",
        2
      ],
      [
        "BioNTech",
        2
      ],
      [
        "UK",
        2
      ]
    ],
    "entity_types_found": [
      "ORG",
      "PRODUCT",
      "PERCENT",
      "DATE",
      "MONEY",
      "GPE"
    ],
    "company_entities": 28,
    "person_entities": 0,
    "financial_entities": 7,
    "entity_density": 0.15053763440860216
  },
  "financial_analysis": {
    "money_amounts": [
      "3.09",
      "24"
    ],
    "percentages": [
      "6.7%",
      "1.7%",
      "1.7%",
      "1.3%",
      "1.3%"
    ],
    "companies": [
      "Pfizer Inc.",
      "PFE",
      "Zacks",
      "PFE",
      "Pfizer",
      "PFE",
      "Pfizer",
      "Astellas",
      "Pfizer",
      "Astellas",
      "Pfizer",
      "PFE",
      "Pfizer",
      "Pfizer",
      "Cantor Fitzgerald",
      "Pfizer",
      "Cantor Fitzgerald",
      "Bernstein",
      "PFE",
      "Bernstein",
      "Pfizer",
      "Pfizer",
      "Pfizer",
      "BioNTech",
      "Moderna",
      "Pfizer",
      "BioNTech",
      "Moderna"
    ],
    "people": [],
    "dates": [
      "year-end",
      "FY2025",
      "FY2025",
      "1+ days ago"
    ],
    "financial_terms": [
      "profit",
      "Profit",
      "earnings",
      "Trading",
      "Stock",
      "stock"
    ],
    "financial_metrics": [],
    "market_indicators": [
      "Rating",
      "Price",
      "price",
      "target",
      "rating"
    ]
  },
  "temporal_analysis": {
    "dates": [
      "year-end",
      "FY2025",
      "FY2025",
      "1+ days ago"
    ],
    "time_expressions": [],
    "temporal_relationships": [
      "next"
    ],
    "quarters": [],
    "years": [],
    "time_periods": []
  },
  "sentiment_analysis": {
    "positive_words": 11,
    "negative_words": 3,
    "positive_ratio": 0.03942652329749104,
    "negative_ratio": 0.010752688172043012,
    "sentiment_score": 0.028673835125448025,
    "sentiment_label": "positive",
    "sentiment_strength": 0.028673835125448025,
    "confidence": 0.2867383512544803
  },
  "industry_analysis": {
    "dominant_industry": "healthcare",
    "industry_scores": {
      "tech": 1,
      "finance": 1,
      "healthcare": 4,
      "energy": 0,
      "retail": 0,
      "automotive": 0,
      "media": 1,
      "industrial": 0,
      "real_estate": 0,
      "telecom": 0,
      "food_beverage": 0,
      "travel": 0,
      "education": 0,
      "professional": 2,
      "mining": 0,
      "aerospace": 0,
      "environmental": 0,
      "cannabis": 0
    },
    "confidence": 0.4444444444444444
  },
  "market_analysis": {
    "market_sentiment": "bullish",
    "bullish_indicators": 2,
    "bearish_indicators": 0,
    "market_conditions": {
      "volatility": "normal",
      "volume": "normal",
      "trend": "bullish"
    },
    "trading_activity": "normal"
  },
  "competitor_analysis": {
    "companies_mentioned": [
      "Pfizer Inc.",
      "PFE",
      "Zacks",
      "PFE",
      "Pfizer",
      "PFE",
      "Pfizer",
      "Astellas",
      "Pfizer",
      "Astellas",
      "Pfizer",
      "PFE",
      "Pfizer",
      "Pfizer",
      "Cantor Fitzgerald",
      "Pfizer",
      "Cantor Fitzgerald",
      "Bernstein",
      "PFE",
      "Bernstein",
      "Pfizer",
      "Pfizer",
      "Pfizer",
      "BioNTech",
      "Moderna",
      "Pfizer",
      "BioNTech",
      "Moderna"
    ],
    "competitive_context": [],
    "competitor_count": 28,
    "has_competitive_language": false
  },
  "risk_analysis": {
    "risk_sentences": [
      "The stock dipped 1.3% amid profit-taking and sell-side caution over valuation.",
      "Pfizer and BioNTech appeal a UK patent ruling favoring Moderna, extending legal uncertainty around COVID-19 vaccine royalties."
    ],
    "risk_count": 2,
    "risk_level": "medium"
  },
  "opportunity_analysis": {
    "opportunity_sentences": [
      "Positive Sentiment:\nPfizer and Astellas report positive Phase 3 EMBARK trial results for XTANDI plus leuprolide in non-metastatic hormone-sensitive prostate cancer, showing improved overall survival.\nPfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study\nPositive Sentiment:\nNew study data suggest abrocitinib could be a game-changer for atopic dermatitis patients.\nPfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis\nPositive Sentiment:"
    ],
    "opportunity_count": 1,
    "opportunity_level": "low"
  },
  "processing_metadata": {
    "timestamp": "2025-07-13T08:48:20.933190",
    "model_used": "en_core_web_trf",
    "text_length": 1979
  }
}